Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arbutus Biopharma Corp ABUS

Healthcare Biotechnology
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran... see more

Recent & Breaking News (NDAQ:ABUS)

Arbutus Provides Corporate Update and Announces Third Quarter 2016 Financial Results

GlobeNewswire November 3, 2016

Patrick Machado Joins Board of Directors of Roivant Sciences

PR Newswire October 19, 2016

Arbutus Recognizes Liver Cancer Awareness Month with Grant to Support the Hepatitis B Foundation’s Patient Storytelling Campaign

GlobeNewswire October 3, 2016

Arbutus to Present HBV Data at the 2016 AASLD Liver Meeting

GlobeNewswire October 1, 2016

Arbutus Reports Interim Multi-Dose Results from Phase II Clinical Trial of ARB-1467 in Patients with Chronic HBV Infection

GlobeNewswire September 29, 2016

Arbutus’ Chief Scientific Officer, Dr. Michael J. Sofia, Awarded the 2016 Lasker~DeBakey Clinical Medical Research Award

GlobeNewswire September 13, 2016

Arbutus to Present at the 2016 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 10, 2016

Arbutus Announces Issuance of Broad New US Patent for LNP Delivery Technology

GlobeNewswire August 8, 2016

Arbutus Provides Corporate Update and Announces Second Quarter 2016 Financial Results

GlobeNewswire August 4, 2016

OMA reports an 11.1% increase in July 2016 passenger traffic

GlobeNewswire August 4, 2016

Arbutus Reports Topline Results from TKM-PLK1 HCC Clinical Trial

GlobeNewswire July 19, 2016

Arbutus to Present Data on New LNP Formulations for Delivery of mRNA at the 2016 Controlled Release Society Conference

GlobeNewswire July 18, 2016

Arbutus to Present mRNA Delivery Data at the 32nd Annual Meeting of the Japan Society of Drug Delivery System

GlobeNewswire June 30, 2016

Arbutus to Participate in Upcoming Investor Conferences

GlobeNewswire June 3, 2016

Arbutus to Present at the 5th Antiviral Drugs Research and Development Conference

GlobeNewswire June 1, 2016

Arbutus Provides Corporate Update and Announces First Quarter 2016 Financial Results

GlobeNewswire May 4, 2016

Arbutus Expands HBV Pipeline

GlobeNewswire May 3, 2016

Arbutus to Provide a Corporate Update and Release First Quarter 2016 Financial Results

GlobeNewswire April 29, 2016

Arbutus to Participate in Upcoming Investor Conferences

GlobeNewswire April 27, 2016

4 Biotech Stocks to Buy at Beaten Down Prices

Accesswire April 27, 2016